ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution

By: PRLog
Miami-based supplement pioneer combines enteric-coated dihydroberberine with a patent-pending (U.S. App. No. 63/837,080) P-gp efflux modulator, targeting the two documented barriers to berberine absorption that most supplements never address

MIAMI - March 19, 2026 - PRLog -- RevGenetics is disrupting the metabolic support market today with the commercial launch of DiBerberine 300x, an advanced enteric-coated dihydroberberine (DHB) supplement. By directly addressing the industry-wide "berberine absorption gap," RevGenetics exposes a flaw found in nearly every major competing brand: the failure to protect the active compound from stomach acid degradation and P-glycoprotein (P-gp) efflux pumps.

"The question we kept asking was: why is the supplement industry selling a mechanism - AMPK activation - with a delivery system that undermines the mechanism?" said RevGenetics founder Anthony Loera. "Most every major brand in the berberine category is selling a standard vegetarian capsule with berberine. Nobody in the supplement industry was solving them in a single product."

Unlike standard formulas, The DiBerberine 300x Triple-Action Protocol sets a new standard by combining:
  • Enteric Capsule Technology: Borrowing from pharmaceutical methods, this acid-resistant capsule bypasses the stomach without dissolving, preventing DHB from reverting to standard berberine HCl and ensuring release in the small intestine.
  • DiBerberine™ Proprietary Blend (500mg per capsule): This leverages the profound pharmacokinetic advantage of DHB. A 2022 study showed a 100mg dose yielded ~6.7x greater plasma exposure than 500mg of standard berberine HCl.
  • RGBooster1: A patent-pending (U.S. App. No. 63/837,080) flavonoid complex. Internal assays demonstrate our Sophora japonica extract is up to 300x more potent than piperine at modulating the P-gp active transport mechanism that expels compounds from intestinal cells.
"Enteric coating isn't new technology," Loera stated. "Applying that technology to DHB was the obvious move. It just hadn't been done in a commercially available formula."

Manufactured in the USA
in a cGMP-certified, third-party tested facility, DiBerberine 300x is now available at revgenetics.com. A 30-day supply (30 enteric capsules) is priced at $44.95.

Health and wellness influencers, practitioners, and marketers interested in partnering with RevGenetics for this launch can access the affiliate program at getlink.revgenetics.com.

Media Contact
RevGenetics
news@revgenetics.com
305-929-3819

Photos: (Click photo to enlarge)

RevGenetics Logo Revgenetics Since 2007 Diberberine Benefits By The Sea Diberberine 300x Front Label Diberberine 300x Group Image


Source: RevGenetics

Read Full Story - Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution | More news from this source

Press release distribution by PRLog

Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.89
+1.51 (0.63%)
AAPL  259.20
-1.28 (-0.49%)
AMD  246.83
+1.79 (0.73%)
BAC  53.35
+0.81 (1.54%)
GOOG  319.21
+3.49 (1.11%)
META  634.53
+4.67 (0.74%)
MSFT  384.37
+13.50 (3.64%)
NVDA  189.31
+0.68 (0.36%)
ORCL  155.62
+17.53 (12.69%)
TSLA  352.42
+3.47 (0.99%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.